Brain virome dysbiosis in Parkinson's disease and multiple system atrophy

Mahin Ghorbani1,2, Giorgio Gabarrini2, Zamaneh Hajikhezri3

  • 1Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.

Frontiers in Microbiology
|November 7, 2025
PubMed

Insights

This study reveals a distinct brain virome in the human putamen, finding higher viral diversity in neurodegenerative diseases like Parkinson's disease (PD) and multiple system atrophy (MSA). These viral signatures may aid in early diagnosis.

Area of Science:

  • Neurovirology
  • Genomics
  • Neurodegenerative Diseases

Background:

  • The human brain virome, particularly in regions affected by Parkinson's disease (PD) and multiple system atrophy (MSA), remains largely uncharacterized.
  • Understanding viral presence in the putamen is crucial given its critical role in these neurodegenerative conditions.

Purpose of the Study:

  • To investigate the presence and diversity of viral elements within the human putamen in cases of PD, MSA, and healthy controls.
  • To identify potential viral biomarkers associated with neurodegenerative diseases.

Main Methods:

  • Whole-genome sequencing data from 32 post-mortem putamen samples (10 PD, 10 MSA, 12 controls) were analyzed.
  • Virome profiling was performed using MetaPhlAn4.
  • Biomarker discovery and validation utilized LEfSe, Wilcoxon, and ROC analyses.

Main Results:

  • Neurodegenerative samples showed significantly higher virome alpha diversity compared to healthy controls.
  • Nine viral species, including Pestivirus A and Human endogenous retrovirus K, were enriched in neurodegenerative samples.
  • Alcelaphine gammaherpesvirus 1 was more abundant in healthy controls.

Conclusions:

  • This pilot study presents the first evidence of a brain virome in the human putamen.
  • A potential link between virome dysbiosis and neurodegenerative diseases is suggested.
  • Distinct viral signatures in PD and MSA could serve as candidate biomarkers for early detection and diagnosis.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
954
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782